Close Menu

hormonal therapy

Adding Verzenio to hormone therapy reduced the risk of relapse by 25 percent, while the PALLAS study, testing another CDK4/6 inhibitor, failed.

Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.

A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.